The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis.
Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, Yang ZY, Mao C, Tang JL. · 2016
Read The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. by Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, Yang ZY, Mao C, Tang JL. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5346692.txt.
Description
Yue-Lun Zhang and co-authors pooled studies of a gene flaw in lung cancer in Oncotarget in 2016. The gene, EGFR, drives growth signals in cells. Flaws in it mark a set of lung tumors that answer to matched drugs. Knowing how common the flaw is, group by group and land by land, guides testing and care.
The team found more than four hundred studies with well over a hundred thousand patients in all. Across the whole set, about a third of patients with non-small-cell lung cancer carried the flaw. Rates ran high in China and low in Europe. Women carried it far more than men, and non-smokers far more than smokers. Tumors of the gland type bore it three times as often as other types. The pooled map gives clinics a firm base for who to test first.
Catalog record
| CREATOR | Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, Yang ZY, Mao C, Tang JL. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |